Targiniq ER is a class II extended-release narcotic used for the management of severe pain that requires around-the-clock treatment. According to the FDA, it is the second extended release or long-acting with approved labeling for its abuse-deterrent properties!
What strengths are available?
Targiniq ER will be available as an extended-release tablet in 10 mg/5 mg, 20 mg/10 mg, and 40 mg/20 mg strengths.
When will Targiniq be available to patients?
At the current time it is unknown. Targiniq ER was approved by the FDA in July 2014, but does not yet have a release date from the manufacturer.
How is Targiniq taken?
Targiniq ER is to be taken every 12 hours and is NOT meant to be used as-needed for pain relief.
What does abuse deterrent mean?
Targiniq is a unique form of extended-release oxycodone which has been specifically formulated to decrease the potential for abuse. Although this medication cannot totally prevent abuse, it will help. The addition of naloxone stops the “feel good” effect users get from snorting or injecting the oxycodone part of the medication. As a result, this formulation is not preferred by oxycodone drug abusers compared to its plain oxycodone counterpart.
Does naloxone have any purpose other than as an abuse deterrent?
Yes. When used alone, naloxone is used for the treatment of opioid drug overdose. Naloxone will either partially or completely reverse the effects of certain narcotics, some examples including heroin, morphine, oxycodone, codeine, and hydrocodone.
Yes. The extended release oxycodone in the new Oxycontin is a crush-resistant, abuse-deterrent formulation. Abuse, in this particular situation, can be–but is not limited to–crushing, snorting, or injecting a medication that is intended for extended-release absorption.